Akebia Therapeutics, Inc. AKBA

About Akebia Therapeutics, Inc. (AKBA): stock profile, AI score and financials

Akebia Therapeutics, Inc. (AKBA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AKBA at 45.6/100 on a composite quality score built from its SEC filings, placing it at rank #1,881 of 2,925 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (18.3) and profitability (22.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 24.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Akebia Therapeutics, Inc. reports quarterly revenue of $49.1M, net income of $-8.9M, an operating margin of -12.9%. Top institutional holders of AKBA by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, AQR CAPITAL MANAGEMENT, based on the most recent SEC filings. AKBA trades on the Nasdaq exchange and files with the SEC under CIK 1517022. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AKBA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Akebia Therapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1517022 →